As a result, it is plausible that pharmacological targeting or mutagenesis of these locations could block Ang II–AT1R binding, thereby preventing severe consequences of COVID-19 when the Ang II–AT1R axis is activated. The gene discussed is AGTR1; the disease is COVID-19.